SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Neuland Laboratories - Quaterly Results

10 May 2024 Evaluate
The sales for the March 2024 quarter moved down to Rs. 3850.10 millions as compared to Rs. 4070.73 millions during the year-ago period.The Company's Net profit for the March 2024 quarter have declined marginally to Rs. 676.06  millions as against Rs. 845.10 millions reported during the corresponding quarter ended.Operating Profit reported a sharp decline to 1121.51 millions from 1277.81 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 3850.10 4070.73 -5.42 15585.80 11911.98 30.84 15585.80 11911.98 30.84
Other Income 53.57 80.64 -33.57 125.44 97.48 28.68 125.44 97.48 28.68
PBIDT 1121.51 1277.81 -12.23 4744.65 2810.56 68.82 4744.65 2810.56 68.82
Interest 36.09 42.89 -15.85 139.97 130.67 7.12 139.97 130.67 7.12
PBDT 1085.42 1234.92 -12.11 4604.68 2679.89 71.82 4604.68 2679.89 71.82
Depreciation 164.62 134.70 22.21 596.99 527.76 13.12 596.99 527.76 13.12
PBT 920.80 1100.22 -16.31 4007.69 2152.13 86.22 4007.69 2152.13 86.22
TAX 244.74 255.12 -4.07 1011.73 520.94 94.21 1011.73 520.94 94.21
Deferred Tax 25.50 1.76 1348.86 15.87 17.04 -6.87 15.87 17.04 -6.87
PAT 676.06 845.10 -20.00 2995.96 1631.19 83.67 2995.96 1631.19 83.67
Equity 129.01 129.01 0.00 129.01 129.01 0.00 129.01 129.01 0.00
PBIDTM(%) 29.13 31.39 -7.20 30.44 23.59 29.02 30.44 23.59 29.02

Neuland Laboratories Share Price

14408.95 -539.25 (-3.61%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×